Eutilex.Co.,Ltd (KOSDAQ: 263050)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,280.00
-235.00 (-9.34%)
Sep 11, 2024, 2:59 PM KST
-38.38%
Market Cap 84.81B
Revenue (ttm) 3.04B
Net Income (ttm) -24.22B
Shares Out 36.79M
EPS (ttm) -658.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 442,590
Open 2,585.00
Previous Close 2,515.00
Day's Range 2,255.00 - 2,585.00
52-Week Range 1,765.00 - 3,925.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. discovers and develops immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops anti-tumor T cell therapy and antibody therapeutics. The company was founded in 2015 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 141
Stock Exchange KOSDAQ
Ticker Symbol 263050
Full Company Profile

Financial Performance

In 2023, Eutilex.Co.,Ltd's revenue was 131.65 million, a decrease of -38.95% compared to the previous year's 215.66 million. Losses were -27.72 billion, -17.08% less than in 2022.

Financial Statements

News

There is no news available yet.